A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset ...

This article makes a valuable contribution to the field by uncovering a molecular mechanism for miRNA intracellular retention, mediated by the interaction of PCBP2, SYNCRIP, and specific miRNA motifs.

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

Researchers from Osaka Metropolitan University have identified a gene that, when activated by metabolic stress, damages ...

Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk ...

The initial investigation of 73 patients with CLL in a discovery cohort revealed a strong association between higher BCL-2 dependence and the presence of favorable genetic biomarkers. Moreover, BCL-2 ...

Antiproliferative and proapoptotic effects were observed in tumour cells but not in fibroblasts or non-malignant tissues. siRNA permutations and diverse overhangs influenced gene silencing efficacy.

When Mary Ann Anderson, MBBS, PhD, FRACP, FRCPA, explains the history of venetoclax, the revolutionary BCL-2 inhibitor that has transformed the management of chronic lymphocytic leukemia (CLL) and ...

The gene encoding B-cell lymphoma-2 (BCL-2) is highly expressed in many hematological malignancies, making it a promising target.